N Lendner, et al. J Pediatr Gastroenterol Nutr. 2024;79:92‐99. Comparison of budesonide vehicles in inducing histologic remission in pediatric eosinophilic esophagitis.

This retrospective study with 111 patients with EoE examined histologic remission with oral viscous budesonide (OVB) and various delivery vehicles (Splenda, honey, syrup or applesauce). Key findings:

• Overall rate of histologic remission with OVB was 52.6% (“which is less than the reported response of approximately 66% for topical steroid therapy”).
• There was no difference in rates of histologic remission or response in mid and distal esophagus, respectively) among the different vehicle types or treatment regimens. Similarly, there was no difference in endoscopic remission or response

My take: It does not seem to matter which delivery vehicle is used for OVB; thus, clinicians should aim for more palatable and cost‐effective vehicles.

Related blog posts:

• Budesonide FDA-Approved for Eosinophilic Esophagitis
• “Tug” Sign For Eosinophilic Esophagitis and EoE Bowel Sounds Tips
• Budesonide for Maintaining EoE Remission
• Head-to-Head: Budesonide vs Fluticasone for Eosinophilic Esophagitis
• Budesonide Looks Better for Eosinophilic Esophagitis